AUS
NZ
UK
CA
USA
IND
Highlights
- (ASX:NTI) secures a positive opinion from the European Medicines Agency for NTI164’s Orphan Medicinal Product Designation.
- The US FDA granted orphan drug status to NTI164 in late 2024, signaling progress for the treatment’s potential approval.
- Rett syndrome affects approximately 350,000 individuals globally, with a market opportunity exceeding $2 billion annually.
(ASX:NTI), a biopharmaceutical company specializing in pediatric neurological disorders, has achieved a major milestone with positive regulatory feedback for its lead drug, NTI164. The European Medicines Agency (EMA) has provided a favorable opinion on the company’s application for Orphan Medicinal Product Designation (OMPD), signaling growing recognition of NTI164’s potential to treat Rett syndrome.
Rett syndrome is a rare genetic disorder that primarily affects females and results from mutations in the MECP2 gene on the X chromosome. The condition significantly impacts brain development, leading to severe cognitive, motor, and communication impairments. With an estimated 350,000 individuals affected worldwide, including around 28,000 in Europe and 15,000 in the United States, the need for effective treatments remains high.
Receiving orphan drug designation provides key advantages, such as regulatory fee reductions, market exclusivity for ten years, and scientific guidance specific to orphan medicines. This regulatory support enhances the pathway to bringing NTI164 to market and offers strategic benefits for (NTI) as it advances through clinical development.
Beyond Europe, NTI164 has also received orphan designation from the US Food and Drug Administration (FDA) in late 2024. This dual recognition highlights the growing confidence in the treatment’s potential, marking an important step towards future approvals in major markets.
The demand for effective Rett syndrome treatments is underscored by the lack of approved therapies currently available. The estimated market for Rett syndrome treatments exceeds $2 billion annually, presenting a significant opportunity for innovation in rare disease therapeutics.
Neurotech International’s progress is further supported through its collaboration with RH Farma Dooel Skopje, a subsidiary of the European Cannabis Company. This partnership plays a crucial role in advancing NTI164’s development, reinforcing the company’s commitment to addressing unmet medical needs in pediatric neurological conditions.
The recent regulatory endorsements from both the EMA and FDA mark a pivotal advancement for (ASX:NTI). As Neurotech continues its clinical trials and regulatory discussions, the momentum surrounding NTI164’s development underscores the broader potential impact on patients and caregivers affected by Rett syndrome.
